CDK2 and prostate carcinoma: Other possible mechanisms underlying prostate cancer resistance to CDK4/6 inhibition that may underpin these results will be explored in detail below and include upregulation of other growth factor pathways such as MAPK and PI3K, CDK2 overexpression, and loss of tumor suppressors such as Rb.